RUNX1-deficient human megakaryocytes demonstrate thrombopoietic and platelet half-life and functional defects in an in vivo murine model: Therapeutic implications
K. Lee, H. S. Ahn, B. Estevez, M. Poncz
This paper shows that RUNX1-deficient human megakaryocytes have thrombopoietic and platelet defects in mice, which can be reversed by a TGFβ inhibitor.
bioRxiv · Sep 12, 2022 · PreprintCancer Biology